Guardian Pharmacy Services Reports Q1 2026 Earnings Amid IRA Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Source: seekingalpha
- Revenue Growth: Guardian Pharmacy Services reported Q1 2026 revenue of $336.6 million, reflecting a 2% year-over-year increase despite a significant 60% decline in pricing for branded drugs under the IRA framework, demonstrating resilience in challenging conditions.
- Adjusted EBITDA Guidance Increase: Management raised full-year adjusted EBITDA guidance to $123 million to $127 million, incorporating a $3 million benefit recognized in Q1, indicating strong profitability amid new policy challenges.
- Increase in Resident and Script Volumes: The company reported a 10% year-over-year increase in total residents to approximately 207,000 and a similar 10% rise in script volumes, highlighting robust market demand and effective expansion of its customer base.
- Capital Markets Activity: The company executed an offering of 6.9 million Class A shares priced at $31 each during the quarter, although it currently has no plans to utilize the newly filed shelf registration, reflecting a cautious approach to capital management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRDN
Wall Street analysts forecast GRDN stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 41.890
Low
34.00
Averages
34.50
High
35.00
Current: 41.890
Low
34.00
Averages
34.50
High
35.00
About GRDN
Guardian Pharmacy Services, Inc. is a pharmacy services company. The Company provides a range of technology-enabled services designed to help residents of long-term care facilities (LTCFs) adhere to drug regimen. It offers compliance packaging service for repackaging and dispensing prescription and non-prescription pharmaceuticals in accordance with physician orders and delivers the medications to LTCFs for administration to individual residents. It organizes each resident’s medications into individual unit dose or multi-unit dose packaging in accordance with specific drug distribution rounds that occur at LTCFs at specific times throughout the day. Its pharmacy workflow software helps to manage and track drug dispensing via a structured and scalable workflow process, including the use of barcode technology. It offers Guardian Compass, which includes dashboards created to help local pharmacies plan, track and optimize business operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Guardian Pharmacy Services Announces Executive Leadership Changes
- Executive Changes: Guardian Pharmacy Services announced executive leadership changes effective July 1, 2026, with current CFO David Morris transitioning to COO, indicating a significant shift in the company's leadership structure.
- Financial Leadership Transition: David Morris has served as CFO since the company's inception, while Will Mudd, appointed as the new CFO, has been with Guardian since 2012, overseeing critical functions such as financial accounting and human resources.
- Strategic Implications: This leadership transition not only reflects a reassessment of the company's future operational strategy but may also impact financial management and operational efficiency, enhancing overall business performance.
- Market Response: Guardian Pharmacy Services reported a non-GAAP EPS of $0.29 for Q1 2026, beating expectations by $0.05, with revenue of $336.6 million exceeding forecasts by $6.71 million, demonstrating robust financial performance ahead of the executive changes.
See More
Guardian Announces Executive Leadership Changes with Forbes Retirement
- Executive Retirement: Guardian's Executive Vice President of Sales & Operations, Kendall Forbes, will retire on July 1, 2026, after 22 years, having significantly contributed to building the company's sales and operations foundation, which has lasting implications for its future.
- New COO Appointment: David Morris will assume the role of Chief Operating Officer, previously serving as CFO, and his deep understanding of the business and financial discipline positions him to lead Guardian into its next growth phase, ensuring a seamless transition in leadership functions.
- New CFO Announcement: Will Mudd has been appointed Chief Financial Officer, previously serving as Senior Vice President of Finance since 2012, where he played a critical role in financial accounting and reporting, ensuring the robustness of the finance organization during the company's transition to a public entity.
- Leadership Depth: These executive changes highlight Guardian's disciplined approach to succession planning and its commitment to developing and advancing internal talent, which is crucial for supporting the company's ongoing growth.
See More
Guardian Pharmacy Q1 Earnings Beat Expectations
- Strong Earnings Performance: Guardian Pharmacy Services reported a Q1 non-GAAP EPS of $0.29, beating expectations by $0.05, which reflects the company's robust profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $336.6 million, exceeding forecasts by $6.71 million, indicating its competitive strength and sustained customer demand, further solidifying its market position.
- Net Income and Adjusted EBITDA: Q1 net income stood at $13.5 million with adjusted EBITDA at $29.8 million, demonstrating positive progress in cost control and operational efficiency, which supports sustainable growth moving forward.
- Optimistic Outlook: The company raised its annual adjusted EBITDA forecast midpoint to $125 million from $122 million while maintaining its revenue outlook midpoint at $1.41 billion, reflecting management's confidence in future performance and recognition of market potential.
See More
Guardian Pharmacy Services Reports Q1 2026 Earnings Amid IRA Challenges
- Revenue Growth: Guardian Pharmacy Services reported Q1 2026 revenue of $336.6 million, reflecting a 2% year-over-year increase despite a significant 60% decline in pricing for branded drugs under the IRA framework, demonstrating resilience in challenging conditions.
- Adjusted EBITDA Guidance Increase: Management raised full-year adjusted EBITDA guidance to $123 million to $127 million, incorporating a $3 million benefit recognized in Q1, indicating strong profitability amid new policy challenges.
- Increase in Resident and Script Volumes: The company reported a 10% year-over-year increase in total residents to approximately 207,000 and a similar 10% rise in script volumes, highlighting robust market demand and effective expansion of its customer base.
- Capital Markets Activity: The company executed an offering of 6.9 million Class A shares priced at $31 each during the quarter, although it currently has no plans to utilize the newly filed shelf registration, reflecting a cautious approach to capital management.
See More
Major Wall Street Rating Updates on Monday
- Cohu Rating Reiteration: Jefferies reiterates its Buy rating on Cohu with a price target of $55, viewing the company as an emerging enabler of higher-complexity semiconductor testing, which could enhance its market position significantly.
- Rollins Upgrade: Rothschild & Co Redburn upgrades Rollins from Neutral to Buy, raising the price target from $51.90 to $66, indicating a 16% upside, as they see the current share price as an attractive entry point for investors.
- Nutrien Upgrade: Barclays upgrades Nutrien from Equal Weight to Overweight, increasing the price target from $80 to $85, anticipating continued strength in the nitrogen segment due to the Iran conflict, which positions the company favorably in the market.
- Galaxy Digital Initiation: Chardan initiates coverage of Galaxy Digital with a Buy rating, highlighting its attractive position in the digital asset ecosystem and potential for integration with traditional financial markets, which could drive future growth.
See More
Guardian Pharmacy Services to Attend 2026 Healthcare Conference
- Conference Participation: Guardian Pharmacy Services will attend the Bank of America 2026 Healthcare Conference in Las Vegas on May 13, 2026, where CEO Fred Burke will participate in a fireside chat at 9:20 a.m. PDT, showcasing the company's leadership in long-term care pharmacy services.
- Investor Engagement: The event will feature a live audio webcast accessible through Guardian Pharmacy Services' website, allowing investors, analysts, media, and the public to engage, thereby enhancing transparency and interaction with stakeholders.
- Business Model: Guardian partners with long-term care facilities to deliver medications and technology-enabled services aimed at improving medication adherence, which helps reduce care costs and enhance clinical outcomes, highlighting its competitive edge in the industry.
- Network Expansion: As of December 31, 2025, Guardian operates 61 pharmacies, with 54 being full-service, serving nearly 205,000 residents, demonstrating its ongoing growth and influence in the long-term care market.
See More
Guardian Pharmacy Services Announces Executive Leadership Changes
- Executive Changes: Guardian Pharmacy Services announced executive leadership changes effective July 1, 2026, with current CFO David Morris transitioning to COO, indicating a significant shift in the company's leadership structure.
- Financial Leadership Transition: David Morris has served as CFO since the company's inception, while Will Mudd, appointed as the new CFO, has been with Guardian since 2012, overseeing critical functions such as financial accounting and human resources.
- Strategic Implications: This leadership transition not only reflects a reassessment of the company's future operational strategy but may also impact financial management and operational efficiency, enhancing overall business performance.
- Market Response: Guardian Pharmacy Services reported a non-GAAP EPS of $0.29 for Q1 2026, beating expectations by $0.05, with revenue of $336.6 million exceeding forecasts by $6.71 million, demonstrating robust financial performance ahead of the executive changes.
See More
Guardian Announces Executive Leadership Changes with Forbes Retirement
- Executive Retirement: Guardian's Executive Vice President of Sales & Operations, Kendall Forbes, will retire on July 1, 2026, after 22 years, having significantly contributed to building the company's sales and operations foundation, which has lasting implications for its future.
- New COO Appointment: David Morris will assume the role of Chief Operating Officer, previously serving as CFO, and his deep understanding of the business and financial discipline positions him to lead Guardian into its next growth phase, ensuring a seamless transition in leadership functions.
- New CFO Announcement: Will Mudd has been appointed Chief Financial Officer, previously serving as Senior Vice President of Finance since 2012, where he played a critical role in financial accounting and reporting, ensuring the robustness of the finance organization during the company's transition to a public entity.
- Leadership Depth: These executive changes highlight Guardian's disciplined approach to succession planning and its commitment to developing and advancing internal talent, which is crucial for supporting the company's ongoing growth.
See More
Guardian Pharmacy Q1 Earnings Beat Expectations
- Strong Earnings Performance: Guardian Pharmacy Services reported a Q1 non-GAAP EPS of $0.29, beating expectations by $0.05, which reflects the company's robust profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $336.6 million, exceeding forecasts by $6.71 million, indicating its competitive strength and sustained customer demand, further solidifying its market position.
- Net Income and Adjusted EBITDA: Q1 net income stood at $13.5 million with adjusted EBITDA at $29.8 million, demonstrating positive progress in cost control and operational efficiency, which supports sustainable growth moving forward.
- Optimistic Outlook: The company raised its annual adjusted EBITDA forecast midpoint to $125 million from $122 million while maintaining its revenue outlook midpoint at $1.41 billion, reflecting management's confidence in future performance and recognition of market potential.
See More
Guardian Pharmacy Services Reports Q1 2026 Earnings Amid IRA Challenges
- Revenue Growth: Guardian Pharmacy Services reported Q1 2026 revenue of $336.6 million, reflecting a 2% year-over-year increase despite a significant 60% decline in pricing for branded drugs under the IRA framework, demonstrating resilience in challenging conditions.
- Adjusted EBITDA Guidance Increase: Management raised full-year adjusted EBITDA guidance to $123 million to $127 million, incorporating a $3 million benefit recognized in Q1, indicating strong profitability amid new policy challenges.
- Increase in Resident and Script Volumes: The company reported a 10% year-over-year increase in total residents to approximately 207,000 and a similar 10% rise in script volumes, highlighting robust market demand and effective expansion of its customer base.
- Capital Markets Activity: The company executed an offering of 6.9 million Class A shares priced at $31 each during the quarter, although it currently has no plans to utilize the newly filed shelf registration, reflecting a cautious approach to capital management.
See More
Major Wall Street Rating Updates on Monday
- Cohu Rating Reiteration: Jefferies reiterates its Buy rating on Cohu with a price target of $55, viewing the company as an emerging enabler of higher-complexity semiconductor testing, which could enhance its market position significantly.
- Rollins Upgrade: Rothschild & Co Redburn upgrades Rollins from Neutral to Buy, raising the price target from $51.90 to $66, indicating a 16% upside, as they see the current share price as an attractive entry point for investors.
- Nutrien Upgrade: Barclays upgrades Nutrien from Equal Weight to Overweight, increasing the price target from $80 to $85, anticipating continued strength in the nitrogen segment due to the Iran conflict, which positions the company favorably in the market.
- Galaxy Digital Initiation: Chardan initiates coverage of Galaxy Digital with a Buy rating, highlighting its attractive position in the digital asset ecosystem and potential for integration with traditional financial markets, which could drive future growth.
See More
Guardian Pharmacy Services to Attend 2026 Healthcare Conference
- Conference Participation: Guardian Pharmacy Services will attend the Bank of America 2026 Healthcare Conference in Las Vegas on May 13, 2026, where CEO Fred Burke will participate in a fireside chat at 9:20 a.m. PDT, showcasing the company's leadership in long-term care pharmacy services.
- Investor Engagement: The event will feature a live audio webcast accessible through Guardian Pharmacy Services' website, allowing investors, analysts, media, and the public to engage, thereby enhancing transparency and interaction with stakeholders.
- Business Model: Guardian partners with long-term care facilities to deliver medications and technology-enabled services aimed at improving medication adherence, which helps reduce care costs and enhance clinical outcomes, highlighting its competitive edge in the industry.
- Network Expansion: As of December 31, 2025, Guardian operates 61 pharmacies, with 54 being full-service, serving nearly 205,000 residents, demonstrating its ongoing growth and influence in the long-term care market.
See More
